Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data
Raymond James maintains a Strong Buy rating and sets a $19.00 price target for Vir Biotechnology (NASDAQ:VIR) stock, reflecting an 78% upside potential from its current $10.65 price. The rating is based on clinical trial results from competitor Mirum Pharmaceuticals, which reported that its Phase 3 AZURE-1 study for brelovitug in chronic hepatitis delta virus infection met its primary endpoint.
Additionally, the firm's studies, including Vir's own pivotal trials, are expected to report results beginning in Q4 2026. Both brelovitug and Vir's tobevibart plus elebsiran combination are anticipated to secure regulatory approval, with market focus on virologic suppression depth and prognostic indicators for long-term histologic outcomes.
Vir Biotechnology's financials have also improved, with a $198.5 million increase in cash and investments for Q2 2026 and a net income of $80.1 million. H.C. Wainwright also upholds a Buy rating for Vir Biotechnology, with a price target of $20.00, based on progress in its hepatitis D virus treatment programs.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
